Nuclear Medicinal/PET Diagnostic center

PIB-PET

Overview

The purpose of screening for Alzheimer’s dementia

We examine the risks of developing into Alzheimer’s dementia for people who have short memories, mild cognitive impairment or those who are concerned about diagnosing Alzheimer’s dementia.
As for demented people, we make a differential diagnosis to find out if it is the symptoms of Alzheimer’s dementia or the cause lies in something else.

Inquiry

Reception hours 9:00~17:00 (excluding Sundays and Holidays)
Telephone 046-223-3636(main line)


About Alzheimer’s dementia

It is a degenerative disease caused in the brain, the initial symptom of the disease is a memory loss followed by, bewilderment of the concept of date and hour, a decrease in initiative, leading to difficulties in continuing social and daily lives, these symptoms eventually develop to a point where the patients disintegrate their personalities.
The cause lies in the amyloid beta protein accumulated in the brain, causing a decline in function of brain cells. This accumulation of amyloid beta protein is considered to occur several decades before the onset of Alzheimer’s dementia.

Confirmed diagnosis for Alzheimer’s dementia is to show the evidence amyloid plaque and neurofibrillary tangle pathologically in posthumous autopsied brain. So, it is difficult to perform confirmed diagnosis for Alzheimer’s dementia by only examining the symptoms in clinic test, as amyloid plaque can’t be detected while the patients’ are alive.


B([11C]PIB), known as Pittsburgh Compound was developed as non-radioactive drug for PET in the US, 2002.It was labeled with positron emissive isotope,(11C) and used as an amyloid maker, by which visualization of the accumulated amyloid protein has been possible with PET imaging and it has led to the development of a new method of imaging test. Objective early diagnosis for memory loss and Alzheimer’s dementia is becoming possible by applying other examinations centered on Amyloid pet testing.

The purpose of screening for Alzheimer’s dementia

We examine the risks of developing into Alzheimer’s dementia for people who have short memories, mild cognitive impairment or those who are concerned about diagnosing Alzheimer’s dementia.
As for demented people, we make a differential diagnosis to find out if it is the symptoms of Alzheimer’s dementia or the cause lies in something else.


1 .[11C]PIB-PET examination

In Alzheimer’s dementia, it is considered that the accumulation of amyloid beta protein occurs several decades before the onset of symptoms such as memory loss which leads to a decrease in function of brain cells, Alzheimer’s dementia occurs by the progression of cognitive dysfunction.

Confirmed diagnosis for Alzheimer’s dementia is to show the evidence that amyloid plaque and neurofibrillary tangle pathologically in posthumous autopsied brain. However, the confirmed diagnosis for Alzheimer’s dementia faced difficulty as the image of amyloid plaque was not able to extract.

B([11C]PIB), known us Pittsburgh Compound was developed as non-radioactive drug for PET at University of Pittsburgh, 2002. It was labeled with positron emissive isotope,(11C) and used as an amyloid maker, by which visualization of the accumulated amyloid protein has been enabled with PIB-PET imaging, it has now become an epoch-making method of imaging test in providing a diagnostic of Alzheimer’s dementia.

From 2004 through June 2008, this examination was performed on approx.2,000 patients in about 40 institutions established around the world. In our hospital, it was performed on approx.300 patients as clinical research from June 2007 through October 2008.

Since November25, 2008, we have been providing this examination for people who are concerned about their memory loss, under the license of its usage from the University of Pittsburgh and GE healthcare.

2. How the examination is performed

[11C]PIB-PET, radiopharmaceutical is created in the hot laboratory established inside the hospital and after putting them through a quality check, we administer it intravenously into the patient’s body, then immediately start the PET scanning, during the scanning, we take serial radiography for 60 minutes and create images.

3. Safety and adverse effect of examination

Until today, no adverse effect generated by this medical agent has been reported from any institution across the world and we have not experienced it in our hospital, either.
Also, the dosage of radiation exposure estimated by undergoing this examination is about the same as a single barium exam. It has almost no negative impact on the human body.

4. PIB-PET image of Alzheimer’s dementia

Normal and healthy individual   Alzheimer’s dementia

5. Things we can know by undergoing this examination

It tells us whether there is accumulation of amyloid protein or not. people who have short memories and mild cognitive impairment have a risk of developing Alzheimer’s dementia in years to come. People with no accumulation of amyloid protein has almost no risk of developing Alzheimer’s dementia.
Patients with dementia can be diagnosed either as Alzheimer’s dementia or complicated dementia caused by other factors.

6. Application for [11C]PIB-PET and Inquiry.

Shonan Atsugi Hospital
Telephone 046-223-3636(main line)
Location Nurumizu 118-1, Atsugi, Kanagawa, 243-8551